About Grupo International

Grupo International Inc., a development stage company, engages in developing and marketing vaccine designed to combat human immunodeficiency virus/AIDS. Proposed Vaccine The company’s proposed vaccine is called NFU.Ac.HIV, which is designed to perform two functions. The first function, which is typical of traditional vaccines, is to develop an immune response in the vaccinated person to prevent human immunodeficiency virus from infecting the human body. The second is to provide therapeutic benefits to people who are already infected by human immunodeficiency virus. The company has completed pre-clinical trials in Russia. The proposed vaccine is directed at the strain found in Russia, parts of Europe, and the Americas, while the proposed vaccine it anticipates preparing for Africa would be directed at the strain prevalent in southern Africa and in India. History The company was formerly known as HIV-VAC Inc and changed its name to Grupo International Inc. in 2010.